PMID- 35402190
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220413
IS  - 2223-4691 (Print)
IS  - 2223-4691 (Electronic)
IS  - 2223-4683 (Linking)
VI  - 11
IP  - 3
DP  - 2022 Mar
TI  - Significance of hyperhomocysteinaemia as an effective marker for vasculogenic 
      erectile dysfunction: a cross-sectional study.
PG  - 397-406
LID - 10.21037/tau-21-953 [doi]
AB  - BACKGROUND: The primary objective of this cross-sectional study aimed at 
      evaluating serum levels of homocysteinemia (Hcy) in a cohort of erectile 
      dysfunction (ED) patients, and at assessing the correlation between Hcy and 
      vasculogenic ED. METHODS: A total of 119 Chinese patients presenting with ED 
      [International Index of Erectile Function (IIEF)-5</=21] were enrolled in this 
      study. The whole cohort was asked to complete the IIEF-5 questionnaire and blood 
      analysis. A detailed medical history, physical examination, nocturnal penile 
      tumescence (NPT) tests and penile color Doppler ultrasonography (pDUS) were 
      performed by a urologist. Based on the pDUS result, they were further categorized 
      into 2 main groups: non-vasculogenic ED (n=79) and vasculogenic ED (n=40). 
      RESULTS: Age and Hcy levels were significantly higher in the vasculogenic ED 
      group compared to the non-vasculogenic ED group (38.45+/-8.51 vs. 32.29+/-7.57 and 
      22.91+/-5.85 vs. 16.31+/-5.23 micromol/L, respectively, P<0.01). Univariate and 
      multivariable regression analyses showed that the incidence of vasculogenic ED 
      raised significantly with the increase of Hcy level. After multivariable 
      adjustment, ED patients with hyperhomocysteinaemia (HHcy) had 13.42 times the 
      odds of vasculogenic ED compared with patients without HHcy (OR: 13.42, 95% CI: 
      3.78 to 47.64). Moreover, the risk of vasculogenic ED was 1.24 (95% CI: 1.04 to 
      1.48, P=0.01) per-unit increase in Hyc concentration for ED with HHcy. In 
      addition, the smoothing curve revealed that Hcy levels were inversely correlated 
      with peak-systolic velocity (PSV) (beta: -0.48, 95% CI: -0.91 to -0.05, P=0.04) in 
      vasculogenic ED patients by multivariate regression analysis. Furthermore, in the 
      analysis of receiver operating characteristic curve, the area under curve for Hcy 
      to predict vasculogenic ED was 0.81 (95% CI: 0.73 to 89) in patients with ED. 
      CONCLUSIONS: These findings suggest a dose-dependent association between Hcy and 
      vasculogenic ED. HHcy was a risk factor for vasculogenic erectile dysfunction. 
      Therefore, HHcy is likely to be a potential indicator to predict and diagnose 
      vasculogenic ED when using pDUS.
CI  - 2022 Translational Andrology and Urology. All rights reserved.
FAU - Wang, Xuesheng
AU  - Wang X
AD  - Department of Urology, China Rehabilitation Research Center, Rehabilitation 
      School of Capital Medical University, Beijing, China.
AD  - Department of Urology, Capital Medical University, Beijing, China.
AD  - University of Health and Rehabilitation Sciences, Qingdao, China.
FAU - Zhang, Fan
AU  - Zhang F
AD  - Department of Urology, China Rehabilitation Research Center, Rehabilitation 
      School of Capital Medical University, Beijing, China.
AD  - Department of Urology, Capital Medical University, Beijing, China.
FAU - Guo, Liqiang
AU  - Guo L
AD  - Department of Urology and Andrology, Center for Reproductive Medicine, Cheeloo 
      College of Medicine, Shandong University, Jinan, China.
AD  - Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First 
      Medical University, Jinan, China.
FAU - Ma, Zhen
AU  - Ma Z
AD  - Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First 
      Medical University, Jinan, China.
FAU - Liao, Limin
AU  - Liao L
AD  - Department of Urology, China Rehabilitation Research Center, Rehabilitation 
      School of Capital Medical University, Beijing, China.
AD  - Department of Urology, Capital Medical University, Beijing, China.
AD  - University of Health and Rehabilitation Sciences, Qingdao, China.
FAU - Yuan, Mingzhen
AU  - Yuan M
AD  - Department of Urology and Andrology, Center for Reproductive Medicine, Cheeloo 
      College of Medicine, Shandong University, Jinan, China.
AD  - Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First 
      Medical University, Jinan, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Transl Androl Urol
JT  - Translational andrology and urology
JID - 101581119
PMC - PMC8984975
OTO - NOTNLM
OT  - Vasculogenic erectile dysfunction
OT  - effective marker
OT  - hyperhomocysteinaemia
OT  - peak systolic velocity
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at 
      https://tau.amegroups.com/article/view/10.21037/tau-21-953/coif). The authors 
      have no conflicts of interest to declare.
EDAT- 2022/04/12 06:00
MHDA- 2022/04/12 06:01
PMCR- 2022/03/01
CRDT- 2022/04/11 05:30
PHST- 2021/10/31 00:00 [received]
PHST- 2022/02/12 00:00 [accepted]
PHST- 2022/04/11 05:30 [entrez]
PHST- 2022/04/12 06:00 [pubmed]
PHST- 2022/04/12 06:01 [medline]
PHST- 2022/03/01 00:00 [pmc-release]
AID - tau-11-03-397 [pii]
AID - 10.21037/tau-21-953 [doi]
PST - ppublish
SO  - Transl Androl Urol. 2022 Mar;11(3):397-406. doi: 10.21037/tau-21-953.